Rise in proteomics research and development of novel methods opened up new avenues for protein therapeutics. Market players have adopted different strategies to advance the research activities about protein therapeutics by determining the existing issues. Collaboration is one of the vital strategies adopted by them to combine expertise of both companies and finding ways to improve outcomes for patients. In addition, researchers across different universities are coming up with novel methods to develop protein-based therapeutics and drug delivery systems. The discovery of novel methods and the demand for advanced development techniques will increase in the coming years. According to the report published by Allied Market Research, the global protein therapeutics market is estimated to reach $566.66 billion by 2030. Following are some of the activities taking place worldwide.
“Growth of the global protein
therapeutics market is attributed to increase in prevalence of chronic
diseases, surge in development of protein-based therapies, and various
strategies adopted by key players of the market. Moreover, increase in
healthcare expenditure and approval of new products are expected to further
drive the market growth during the forecast period”.
Collaboration is one of the major
strategies adopted by market players to combine capabilities and develop
advanced products by addressing the areas in need. Blueprint Medicines
Corporation joined hands with Proteovant Therapeutics for development of
advanced targeted protein degrader therapies. The targeted protein degrader
utilizes the natural protein system of the body and offers a potential to
develop new medicine for various diseases.
Through the collaboration between two
companies, Proteovant's artificial intelligence (AI)-enhanced targeted protein
degradation (TPD) platform will be utilized along with expertise in precision
medicine of Blueprint. Novel TPD products will be developed through extensive
research and development activities. Newly developed products will be
commercialized by both companies. Recent advancements in the field of TPD
created opportunities for expansion of Blueprint’s core kinase capabilities and
devise new ways to treat various diseases. The collaboration will help
Blueprint in expanding its platform more rapidly than before. In addition, both
companies will be able to improve outcomes of patients with cancer and blood
disorders.
Along with the strategy of
collaboration, researchers from different universities worldwide developed novel
drug delivery systems utilizing protein therapeutics. Researchers from Nanyang
Technological University, Singapore (NTU Singapore) developed a method of drug
delivery into human cells with the help of protein-based microdroplets. This
discovery provides safer, faster, more effective, and better method than
existing methods for cancer treatment, gene therapy, and vaccine delivery.
These microdroplets are made up of peptides and have an ability to encase huge
biomacromolecules. These molecules carry drugs inside them and delivery to the
desired cells. This provides an advantage over the existing synthetic carriers.
Impact of COVID-19 Pandemic on the Protein Therapeutics Market
The COVID-19 outbreak is anticipated to have a positive
impact on the protein therapeutics market. A huge number of clinics and
hospitals across the globe were restructured to increase the hospital capacity
for patients diagnosed with COVID-19.
By
product, the market is segmented into monoclonal antibodies, insulin, fusion
protein, erythropoietin, interferon, human growth hormone, and follicle stimulating
hormone. The monoclonal antibodies segment generated maximum revenue in 2020,
accounting for $136.9 billion. The fusion protein segment is expected to
witness highest CAGR of 9.5% during the forecast period.
0 Comments